News

SFGate15d
Arbutus: Q1 Earnings Snapshot
WARMINSTER, Pa. (AP) — WARMINSTER, Pa. (AP) — Arbutus Biopharma Corp. (ABUS) on Wednesday reported a loss of $24.5 million in its first quarter. On a per-share basis, the Warminster ...
Yahoo Finance1d
Arbutus Biopharma Corporation (ABUS)
WARMINSTER, Pa. AP) — Arbutus Biopharma Corp. ABUS) on Wednesday reported a loss of $24.5 million in its first quarter. Here is how Editas Medicine (EDIT) and Arbutus Biopharma (ABUS ...
Morningstar22d
Arbutus Presents Clinical Trial Data from its Two HBV Assets, Imdusiran and AB-101, at the European Association for the Study of the Liver (EASL) Congress 2025
May 07, 2025 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease ...
Nasdaq22d
Arbutus Biopharma Reports Positive Phase 2a Results for Imdusiran in Combination with VTP-300 and Low Dose Nivolumab in Chronic Hepatitis B Patients at EASL 2025
Arbutus Biopharma Corporation announced promising data from a late-breaker poster presentation at the EASL Congress 2025, revealing that its treatment combining imdusiran, a RNAi therapeutic, with ...
Seeking Alpha2d
ABUS Arbutus Biopharma Corporation
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline ...